N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-D]pyrimidin-1-YL]-phenyl}-cyclopropanecarboxamide dimethyl sulfoxide solvate as an MEK1/2 inhibitor
Novel MEK1, MEK2 and MEK1/2 inhibitors which have lower toxicity in long-term dosage, including the novel compound N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-cyclopropanecarboxamide dimethyl sulfoxide solvate according to formula 1:
1. A compound having a structure according to formula 1:
2. A pharmaceutically-acceptable composition comprising the compound of claim 1 as an active ingredient.
3. The pharmaceutically-acceptable composition of claim 2 , wherein the active ingredient exhibits inhibitor properties for one or both of MEK1 and MEK2.
4. The pharmaceutically-acceptable composition of claim 2 , wherein the active ingredient is present in a therapeutically effective amount.
5. The pharmaceutically-acceptable composition of claim 2 , further comprising one or more pharmaceutically acceptable excipients.
6. The pharmaceutically-acceptable composition of claim 2 , where the composition is in the form of tablets, capsules, or solutions for injection.
7. The pharmaceutically-acceptable composition of claim 6 , where the composition is placed in a pharmaceutically acceptable container.
8. A method of preparing a compound according to claim 1 , comprising treating a compound according to formula 2 or its salt, with cyclopropanecarboxylic acid or an activated derivative of cyclopropanecarboxylic acid